ArticleProceedings of the National Academy of Sciences of the United States of America2025
eIF4A controls translation of estrogen receptor alpha and is a therapeutic target in advanced breast cancer.
Abstract read
In one paragraph
Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Targeting RNA binding proteins with small-molecule inhibitors: Advances, challenges, and therapeutic opportunities.Acta pharmaceutica Sinica. B · 2026Review
- ESR1 fusions in breast cancer: functions, mechanisms and therapeutic opportunities.Translational breast cancer research : a journal focusing on translational research in breast cancer · 2026Review
- From ribosomopathies to therapeutic targets: ribosomal alterations in pediatric leukemogenesis and tumorigenesis.Frontiers in oncology · 2026Review
- Combined HDAC and eIF4A inhibition: A novel epigenetic therapy for pancreatic ductal adenocarcinoma.Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy · 2026Article
- Broad-spectrum antiviral activity of the synthetic rocaglate zotatifin against Mayaro virus and other viruses.Frontiers in cellular and infection microbiology · 2026Article
- Spatial Transcriptomics Reveals Transcriptomic and Immune Microenvironment Reprogramming during Thyroid Carcinoma Dedifferentiation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Targeting AMPK for Cancer Therapy: Metabolic Reprogramming as a Therapeutic Strategy.Oncology research · 2025Review
- Dynamic methylation and expression of alternative promoters for oestrogen receptor alpha in cell line models of fulvestrant resistance.Molecular oncology · 2025Article
- Auraptene Boosts the Efficacy of the Tamoxifen Metabolites Endoxifen and 4-OH-Tamoxifen in a Chemoresistant ER+ Breast Cancer Model.Pharmaceutics · 2024Article
Corrections and comments
- Update of
Authors and funding
27 authors.
Jacob A BoyerLouis V. Gerstner Jr. Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, NY 10065.ORCID 0009-0003-6695-1423
Ezra Y RosenDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
Malvika SharmaProgram in Molecular Pharmacology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065.ORCID 0000-0002-2695-1635
Madeline A DorsoHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065.ORCID 0000-0002-4343-930X
Nicholas MaiDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065.ORCID 0000-0002-1900-7945
Corina AmorLouis V. Gerstner Jr. Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
Jason M ReiterProgram in Molecular Pharmacology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
Ram KannanDepartment of Cancer Biology and Genetics, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
Sunyana GadalProgram in Molecular Pharmacology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065.ORCID 0000-0003-3073-4067
Jianing XuProgram in Molecular Pharmacology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
Matthew MieleMicrochemistry and Proteomics Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
Zhuoning LiMicrochemistry and Proteomics Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
Xiaoping ChenAntitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
Qing ChangAntitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY 10065.ORCID 0000-0001-7406-8479
Fresia ParejaDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
Stephan WorlandDepartment of Cancer Biology, eFFECTOR Therapeutics, Inc., San Diego, CA 92121.ORCID 0000-0001-8924-253X
Douglas WarnerDepartment of Cancer Biology, eFFECTOR Therapeutics, Inc., San Diego, CA 92121.
Sam SperryDepartment of Cancer Biology, eFFECTOR Therapeutics, Inc., San Diego, CA 92121.
Gary G ChiangDepartment of Cancer Biology, eFFECTOR Therapeutics, Inc., San Diego, CA 92121.ORCID 0000-0003-3004-7400
Peggy A ThompsonDepartment of Cancer Biology, eFFECTOR Therapeutics, Inc., San Diego, CA 92121.ORCID 0009-0009-9194-5870
Guangli YangThe Organic Synthesis Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY 10065.ORCID 0000-0002-5097-5266
Ouathek OuerfelliThe Organic Synthesis Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY 10065.ORCID 0000-0002-7038-0219
Alexander DrilonDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
Elisa de StanchinaAntitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY 10065.ORCID 0000-0002-3873-315X
Hans-Guido WendelDepartment of Cancer Biology and Genetics, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
Sarat ChandarlapatyDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065.ORCID 0000-0003-4532-8053
Neal RosenProgram in Molecular Pharmacology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065.ORCID 0000-0002-8307-654X
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4MThe Role of Focal Oncogene Amplifications in Lung CancerP01CA129243 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Andrea Ventura · 2007 to 2026
$31.2MTargeting Polθ to Overcome PARP Inhibitor Resistance in Homologous Recombination Deficient Breast CancerP50CA247749 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Sarat Chandarlapaty, Simon N. Powell · 2020 to 2026
$16.3MStudies on oncoprotein-induced feedback: Basic and therapeutic implicationsR35CA210085 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ROSEN, NEAL · 2016 to 2022
$7.3MTowards targeting the lymphoma microenvironmentR35CA252982 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Hans-Guido Wendel · 2020 to 2026
$6.2MDefining the impact of mutant oncogene zygosityR01CA245069 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHANDARLAPATY, SARAT · 2020 to 2024
$2.0MOrganic Synthesis at the Service of Biology and MedicineR50CA243895 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Ouathek Ouerfelli · 2019 to 2026
$1.9MHHS | NIH | National Cancer Institute (NCI) CA008748HHS | NIH | National Cancer Institute (NCI) CA129243HHS | NIH | National Cancer Institute (NCI) CA210085HHS | NIH | National Cancer Institute (NCI) CA243895HHS | NIH | National Cancer Institute (NCI) CA245069HHS | NIH | National Cancer Institute (NCI) CA24779HHS | NIH | National Cancer Institute (NCI) CA252982NCI NIH HHS P01 CA129243NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA247749NCI NIH HHS R01 CA245069NCI NIH HHS R35 CA210085NCI NIH HHS R35 CA252982NCI NIH HHS R50 CA243895
Abstract
Most breast cancers depend on hormone-stimulated estrogen receptor alpha (ER) activity and are sensitive to ER inhibition. Resistance can arise from activating mutations in the gene encoding ER (
Indexed as
Breast NeoplasmsEstrogen Receptor alphaEukaryotic Initiation Factor-4AProtein BiosynthesisAnimalsCell Line, TumorFemaleFulvestrantGene Expression Regulation, NeoplasticHumansMCF-7 CellsMiceXenograft Model Antitumor AssaysESR1 protein, humanEstrogen Receptor alphaEukaryotic Initiation Factor-4AFulvestrantbreast cancereIF4Aestrogen receptortranslationzotatifin
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.